药物基因组学
加药
医学
药物遗传学
药理学
临床试验
治疗药物监测
药品
药代动力学
重症监护医学
生物信息学
内科学
生物
基因型
基因
生物化学
作者
Raffaele Di Francia,Angela De Monaco,Mariangela Saggese,Giancarla Iaccarino,Stefania Crisci,Ferdinando Frigeri,Rosaria De Filippi,Massimiliano Berretta,Antonio Pinto
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2018-05-22
卷期号:18 (5): 499-511
被引量:48
标识
DOI:10.2174/1568009617666170208162841
摘要
Drugs for targeted therapies are primarily Small Molecules Inhibitors (SMIs), monoclonal antibodies (mAbs), interfering RNA molecules and microRNA. The use of these new agents generates a multifaceted step in the pharmacokinetics (PK) of these drugs. Individual PK variability is often large, and unpredictability observed in the response to the pharmacogenetic profile of the patient (e.g. cytochome P450 enzyme), patient characteristics such as adherence to treatment and environmental factors.This review aims to overview the latest anticancer drugs eligible for targeted therapies and the most recent finding in pharmacogenomics related to toxicity/resistance of either individual gene polymorphisms or acquired mutation in a cancer cell. In addition, an early outline evaluation of the genotyping costs and methods has been taken into consideration. Future Outlook: To date, therapeutic drug monitoring (TDM) of mAbs and SMIs is not yet supported by heavy scientific evidence. Extensive effort should be made for targeted therapies to better define concentration-effect relationships and to perform comparative randomized trials of classic dosing versus PK-guided adaptive dosing. The detection of individual pharmacogenomics profile could be the key for the oncologists that will have new resources to make treatment decisions for their patients in order to maximize the benefit and minimize the toxicity. Based on this purpose, the clinician should evaluate advantages and limitations, in terms of costs and applicability, of the most appropriate pharmacological approach to performing a tailored therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI